Should individual PI3 kinase isoforms be targeted in cancer? - Wikidata - awgldk - TriplyDB

Should individual PI3 kinase isoforms be targeted in cancer?

Should individual PI3 kinase isoforms be targeted in cancer?

http://www.wikidata.org/entity/Q24309044

about

Integrin/Fak/Src-mediated regulation of cell survival and anoikis in human intestinal epithelial crypt cells: selective engagement and roles of PI3-K isoform complexes The PI3K pathway as drug target in human cancer Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer PI3K at the crossroads of tumor angiogenesis signaling pathways Selective inhibition of retinal angiogenesis by targeting PI3 kinase Phosphatidylinositol-3-kinase p110γ contributes to bile salt-induced apoptosis in primary rat hepatocytes and human hepatoma cells Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.Activity of any class IA PI3K isoform can sustain cell proliferation and survival.The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.RAS Interaction with PI3K: More Than Just Another Effector Pathway Exploring the transcriptome space of a recombinant BHK cell line through next generation sequencing.Role of phosphoinositide 3-OH kinase p110β in skeletal myogenesis Using inositol as a biocompatible ligand for efficient transgene expression.Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation.Clinical development of phosphatidylinositol-3 kinase pathway inhibitors Will PI3K pathway inhibitors be effective as single agents in patients with cancer?Autophagy is decreased in triple-negative breast carcinoma involving likely the MUC1-EGFR-NEU1 signalling pathway.Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.Prostate cancer - a biomarker perspective.Disruption of Abi1/Hssh3bp1 expression induces prostatic intraepithelial neoplasia in the conditional Abi1/Hssh3bp1 KO mice.Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.p110δ PI3 kinase pathway: emerging roles in cancer.PI3K p110β subunit in leptin receptor expressing cells is required for the acute hypophagia induced by endotoxemia.Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome.Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing.Potential role of PI3K inhibitors in the treatment of breast cancer.The PI3K signaling pathway mediates the biological effects of leptin.Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.AKT-independent PI3-K signaling in cancer - emerging role for SGK3.The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology.Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.

P2860

15a16212bd293c3bfca712c2c620027460346104

P248

Q24306865-5BC81CC2-D6C5-4AB7-94D9-3B9685DB1B1D Q24632283-39D6C4B8-2364-4FAA-995A-A330D9A32889 Q26862550-FAF992C1-719D-4596-AD76-F4C3747287B9 Q28396795-5DD1D313-3DAB-4B3E-90DB-1A371AAB330D Q28471888-8E3EC9AE-D6A6-412C-B2B3-F600ED18D756 Q28576580-1414E76D-C00D-4680-B21D-DD8BD6B80592 Q33493174-AA03C59C-FF57-4CA9-A7F7-A0B83B6A54D8 Q33674643-00F9F984-3C84-4F41-8650-7AFD6754AAD0 Q33770769-B01F87BD-F2B6-4CCB-9556-38B870EB1084 Q33820455-50D29A44-DE88-4F8E-BE0D-AE857338F718 Q33832537-009B8207-3870-47DE-A42F-8A6D4AFC872A Q33952917-2D1F4514-5F0D-476E-B585-3D798E223E27 Q34024558-20ECFF7F-81CB-4654-87FA-DFBED411BCCB Q34202692-ECEF20F5-5278-4F85-80D2-20BE0B361524 Q35046301-31546FBE-0C95-4285-87CC-105285FE11C2 Q35165157-1B7CD28A-8F15-44DD-AE51-8B6718AF6B6A Q35491335-0DF12394-CAE3-4FF1-BBA4-31F86F1FB66D Q35550765-63D83162-C5A2-4720-8F85-7437D9C9E218 Q35566234-8A02AC82-8D94-41CC-AA84-E58E3A77FA26 Q35764392-DAE50E0C-AB8F-4007-BE4F-F5FDDB2D9884 Q35853834-2FCE8C41-890B-4092-87E4-309196E948A0 Q35861503-1625550F-AFC0-4B3B-AFB4-A665251CDDA4 Q35992814-222537A1-7F2A-4934-82DC-B41AC4864A77 Q36415133-AA2D53BE-F96A-4EC0-AB9E-894FA454EA70 Q36536821-9BBFC59B-2C6F-41AF-986E-176FA1434C20 Q36647928-8741B249-EC8B-484D-B972-CFEA914DF186 Q36928732-C15D381E-098D-4DD6-B110-BD1DB5970F77 Q37064604-A246682E-0FEB-4814-9390-024CB30B79FE Q37309754-458D70A8-77B6-43CE-9771-4F3D6E8B7440 Q37521382-E79DE429-285A-412B-B5D4-5B65D776D147 Q37679937-1754B9D4-B805-4192-85A6-F2551EE49425 Q37698190-F02058F0-B2BD-432A-9ABE-BF5BE1198429 Q37783617-61E7F902-3B89-454F-A67A-FE5E6FF9E616 Q37810478-E9A52F57-208E-4F1C-B29B-83FCF8FC149D Q37886009-4B2BB1EE-BA2E-4706-8EA5-4CB56AAB826F Q38042638-20CDAE8C-5CF9-4824-AE7D-6C5ACEE1914D Q38134714-622297F7-866F-481B-8D68-98C79AEA69EC Q38166578-B3D7B908-DF1C-4F01-9E3B-CB378D840006 Q38745816-F7666547-F5F6-439E-8DAC-5792FB4594CB Q38825945-B8435D06-FDA1-45BC-8C15-9BCB71B99CB6

P2860

Should individual PI3 kinase isoforms be targeted in cancer?

http://www.wikidata.org/entity/Q24309044

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Should individual PI3 kinase isoforms be targeted in cancer?

@ast

Should individual PI3 kinase isoforms be targeted in cancer?

@en

Should individual PI3 kinase isoforms be targeted in cancer?

@en-gb

Should individual PI3 kinase isoforms be targeted in cancer?

@nl

type

label

Should individual PI3 kinase isoforms be targeted in cancer?

@ast

Should individual PI3 kinase isoforms be targeted in cancer?

@en

Should individual PI3 kinase isoforms be targeted in cancer?

@en-gb

Should individual PI3 kinase isoforms be targeted in cancer?

@nl

prefLabel

Should individual PI3 kinase isoforms be targeted in cancer?

@ast

Should individual PI3 kinase isoforms be targeted in cancer?

@en

Should individual PI3 kinase isoforms be targeted in cancer?

@en-gb

Should individual PI3 kinase isoforms be targeted in cancer?

@nl

P1433

Q24309044-3825BBCA-FBB6-40D3-A939-0993ED2D0AA2

P1476

Q24309044-ED0864CC-FCCB-4FD2-8E58-2AED9453D349

P2093

Q24309044-22305609-6A5C-4FFB-8933-EEEE1B861CF9

Q24309044-41E7110F-F54C-4687-90FB-27F44A4D03BF

Q24309044-C1315EBA-57D0-4903-A4E2-1AC349E2EC43

P2860

Q24309044-00CDE462-4164-4ED5-A771-D146E034998F

Q24309044-07A5F578-C3F4-44EE-B6CA-334CE3527192

Q24309044-08302AA1-B11E-457F-8061-CFBCDEDE3D2D

Q24309044-0886BE27-E759-47BA-B09D-1EB83D60957D

Q24309044-0CE5AA2A-CA72-43BF-882E-063E8670C8E6

Q24309044-1049DDD5-A4C4-4DB9-997A-512507A1C2E5

Q24309044-13C54D07-4D5D-4AB0-92C4-FBC63F0FB7E3

Q24309044-148AAE25-A931-43FF-9BD5-9CBDB261FBB5

Q24309044-15F6097A-CEE4-4859-B450-A86C65077E19

Q24309044-217585C5-E6EB-4FBC-92E6-BC48455A4BF7

P304

Q24309044-78DF8D49-8035-4A6B-874B-CF2C7853B3BF

P31

Q24309044-9DAA69A9-E05C-49B4-9F07-6DA0A761BBC3

P3181

Q24309044-2ABACF38-CB3C-47BC-8528-A8B5A9087B45

P356

Q24309044-48E65328-A1CB-4E43-8EB5-1F14B4D493DA

P407

Q24309044-48068BEC-B172-4FF9-99C1-D98147C82F62

P433

Q24309044-3538F6B1-4652-4241-BA15-B3DFDF96140A

P478

Q24309044-3555A9CF-D1D6-405C-86A9-03E838B891A2

P577

Q24309044-C058F9DF-B802-40AD-A541-DED2C3071253

P5875

Q24309044-8DA58BFF-086E-4778-BED6-5574812C50F6

P698

Q24309044-30F05D8F-FC49-4485-9BE8-4C37483CC99D

P921

Q24309044-0D0FC104-E23A-4C19-92FF-798FE52B9E65

Q24309044-28379BF7-E7DF-4CF7-9215-FBDFE1F4E845

Q24309044-583C253B-BE06-4897-9E31-782BE01A6B76

P932

Q24309044-3780CB71-1853-4097-BBD7-0EAE7318632E

P3181

P356

J.CEB.2008.12.007

P1433

Current Opinion in Cell Biology

P1476

Should individual PI3 kinase isoforms be targeted in cancer?

@en

P2093

Jean J Zhao

http://www.w3.org/2001/XMLSchema#string

Shidong Jia

http://www.w3.org/2001/XMLSchema#string

Thomas M Roberts

http://www.w3.org/2001/XMLSchema#string

P2860

Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice

Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

An integrated genomic analysis of human glioblastoma multiforme

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit

P304

199-208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3159586

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CEB.2008.12.007

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23988160

http://www.w3.org/2001/XMLSchema#string

P698

19200708

http://www.w3.org/2001/XMLSchema#string

P921

endothelial cell migration

Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

P932

3142565

http://www.w3.org/2001/XMLSchema#string